BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30584089)

  • 1. Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome.
    Leung KK; Nguyen A; Shi T; Tang L; Ni X; Escoubet L; MacBeth KJ; DiMartino J; Wells JA
    Proc Natl Acad Sci U S A; 2019 Jan; 116(2):695-700. PubMed ID: 30584089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
    Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
    Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
    Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
    Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
    Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
    PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
    Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT
    Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.
    Al-Jamal HA; Mat Jusoh SA; Hassan R; Johan MF
    BMC Cancer; 2015 Nov; 15():869. PubMed ID: 26547689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes.
    Wang H; Li Y; Lv N; Li Y; Wang L; Yu L
    Ann Hematol; 2018 Nov; 97(11):2025-2038. PubMed ID: 30084010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMG1 acts as a novel potential tumor suppressor with epigenetic inactivation in acute myeloid leukemia.
    Du Y; Lu F; Li P; Ye J; Ji M; Ma D; Ji C
    Int J Mol Sci; 2014 Sep; 15(9):17065-76. PubMed ID: 25257528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms.
    Schmelz K; Sattler N; Wagner M; Lübbert M; Dörken B; Tamm I
    Leukemia; 2005 Jan; 19(1):103-11. PubMed ID: 15510208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.
    Tibes R; Al-Kali A; Oliver GR; Delman DH; Hansen N; Bhagavatula K; Mohan J; Rakhshan F; Wood T; Foran JM; Mesa RA; Bogenberger JM
    J Hematol Oncol; 2015 Oct; 8():114. PubMed ID: 26483188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding.
    Mujahed H; Miliara S; Neddermeyer A; Bengtzén S; Nilsson C; Deneberg S; Cordeddu L; Ekwall K; Lennartsson A; Lehmann S
    Blood; 2020 Jul; 136(3):339-352. PubMed ID: 32232485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.
    Liu HB; Urbanavicius D; Tan P; Spencer A; Dear AE
    Int J Oncol; 2014 Oct; 45(4):1742-8. PubMed ID: 25051119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The DNA methylation inhibitor induces telomere dysfunction and apoptosis of leukemia cells that is attenuated by telomerase over-expression.
    Zhang X; Li B; de Jonge N; Björkholm M; Xu D
    Oncotarget; 2015 Mar; 6(7):4888-900. PubMed ID: 25682873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.
    Curik N; Burda P; Vargova K; Pospisil V; Belickova M; Vlckova P; Savvulidi F; Necas E; Hajkova H; Haskovec C; Cermak J; Krivjanska M; Trneny M; Laslo P; Jonasova A; Stopka T
    Leukemia; 2012 Aug; 26(8):1804-11. PubMed ID: 22343522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.
    Goodyear O; Agathanggelou A; Novitzky-Basso I; Siddique S; McSkeane T; Ryan G; Vyas P; Cavenagh J; Stankovic T; Moss P; Craddock C
    Blood; 2010 Sep; 116(11):1908-18. PubMed ID: 20530795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.
    Ørskov AD; Treppendahl MB; Skovbo A; Holm MS; Friis LS; Hokland M; Grønbæk K
    Oncotarget; 2015 Apr; 6(11):9612-26. PubMed ID: 25823822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine.
    Martín I; Navarro B; Serrano A; Villamón E; Calabuig M; Solano C; Chaves FJ; Yagüe N; Orts M; Amat P; Fuentes A; Seda E; García F; Hernández-Boluda JC; Tormo M
    Ann Hematol; 2020 Mar; 99(3):527-537. PubMed ID: 31989250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of SPINT2/HAI-2 by Azacytidine in bone marrow mesenchymal stromal cells affects leukemic stem cell survival and adhesion.
    Roversi FM; Cury NM; Lopes MR; Ferro KP; Machado-Neto JA; Alvarez MC; Dos Santos GP; Giardini Rosa R; Longhini AL; Duarte ADSS; Pericole FV; Favaro P; Yunes JA; Saad STO
    J Cell Mol Med; 2019 Feb; 23(2):1562-1571. PubMed ID: 30484958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
    Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.